S-003
R(-)-Selegiline solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
别名:
(-)-Deprenyl
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C13H17N
化学文摘社编号:
分子量:
187.28
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
200-659-6
MDL number:
InChI key
MEZLKOACVSPNER-GFCCVEGCSA-N
InChI
1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1
SMILES string
C[C@@H](N(CC#C)C)CC1=CC=CC=C1
grade
certified reference material
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in methanol
technique(s)
gas chromatography (GC): suitable, liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
Gene Information
human ... MAOB(4129)
General description
A Certified Spiking Solution® suitable for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis, or urine drug testing. Selegiline is an antidepressant, which belongs to the phenethylamine class of drugs. It is sold under the trade names Anipryl®, Emsam®, and Zelapar® for treatment of Parkinson′s disease, depression, and senile dementia.
Legal Information
Anipryl is a registered trademark of Deprenyl Inc.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Emsam is a registered trademark of Somerset Pharmaceuticals, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zelapar is a registered trademark of Valeant Pharmaceuticals North America LLC
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes
存储类别
3 - Flammable liquids
wgk
WGK 2
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Keiko Inaba-Hasegawa et al.
Journal of neural transmission (Vienna, Austria : 1996), 120(3), 435-444 (2012-09-13)
Type B monoamine oxidase (MAO-B) is proposed to be involved in the pathogenesis of neurodegenerative disorders, such as Parkinson's disease, through oxidative stress and synthesis of neurotoxins. MAO-B inhibitors, rasagiline and selegiline [(-)deprenyl], protect neuronal cells by direct intervention in
Joanna M Krysiak et al.
Angewandte Chemie (International ed. in English), 51(28), 7035-7040 (2012-06-13)
High profile: new activity-based protein profiling (ABPP) probes have been designed that target exclusively monoamine oxidases A and B within living cells (see picture; FAD=flavin adenine dinucleotide, FMN=flavin monodinucleotide). With these probes it could be shown that the MAO inhibitor
Chi-Un Pae et al.
The Journal of clinical psychiatry, 73(5), 661-668 (2012-06-16)
The objective of this analysis is to present the safety profile of selegiline transdermal system (STS) in clinical practice after US Food and Drug Administration approval by analyzing reported postmarketing adverse events (AEs). Deidentified data were obtained on AEs, regardless
Jorge A Zavala et al.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 19(9), 1298-1299 (2012-06-23)
Pramipexole is a non-ergot dopamine agonist that is used frequently as a single therapy or in combination for the management of Parkinson's disease. Common side effects are daytime drowsiness, hypotension, hallucinations and compulsive behaviour. We describe a patient who developed
Dhaval R Kalaria et al.
International journal of pharmaceutics, 438(1-2), 202-208 (2012-09-08)
The objective was to investigate the anodal iontophoresis of the MAO-B inhibitors rasagiline (RAS) and selegiline (SEL) across porcine and human skin in vitro. Passive delivery of RAS and SEL from aqueous solution was minimal; however, increasing current density from
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持